Trial reportArteriosclerosis, thrombosis, and vascular biology2008
Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials.
Trial report in Arteriosclerosis, thrombosis, and vascular biology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Relation between high density lipoprotein particles concentration and cardiovascular events: a meta-analysis.Lipids in health and disease · 2018Pooled it
- Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes.Annals of internal medicine · 2009Pooled it
- Long-Term Changes to Cardiovascular Biomarkers After Hormone Therapy in the Women's Health Initiative Hormone Therapy Clinical Trials.Obstetrics and gynecology · 2025Trial
- Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials.Menopause (New York, N.Y.) · 2013Trial
- Submaximal exercise coronary artery flow increases in postmenopausal women without coronary artery disease after estrogen and atorvastatin.Menopause (New York, N.Y.)Trial
- Perimenopausal transdermal estradiol replacement reduces serum HDL cholesterol efflux capacity but improves cardiovascular risk factors.Journal of clinical lipidologyTrial
- Surrogate disease markers as substitutes for chronic disease outcomes in studies of diet and chronic disease relations.The American journal of clinical nutrition · 2017Article
- Hepatitis C Virus-Associated Alterations in Lipid and Lipoprotein Levels: Helpful or Harmful to the Heart?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017Article
- Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes.Journal of lipid research · 2016Article
- Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis.Diabetes care · 2015Article
- The emergence of proton nuclear magnetic resonance metabolomics in the cardiovascular arena as viewed from a clinical perspective.Atherosclerosis · 2014Review
- HIV/hepatitis C virus coinfection ameliorates the atherogenic lipoprotein abnormalities of HIV infection.AIDS (London, England) · 2014Article
- High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).Journal of the American College of Cardiology · 2012Article
- Statins in the management of dyslipidemia associated with chronic kidney disease.Nature reviews. Nephrology · 2012Review
- The role of PRKCH gene variants in coronary artery disease in a Chinese population.Molecular biology reports · 2012Article
- Long-term prospective study of the influence of estrone levels on events in postmenopausal women with or at high risk for coronary artery disease.TheScientificWorldJournal · 2012Article
- Physical activity, hormone replacement therapy, and the presence of coronary calcium in midlife women.Women & health · 2012Article
- Estrogen receptor polymorphisms and the vascular effects of hormone therapy.Arteriosclerosis, thrombosis, and vascular biology · 2011Article
- Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.Drug design, development and therapy · 2011Review
- Gender differences in the cardiovascular effect of sex hormones.Nature reviews. Cardiology · 2009Review
Corrections and comments
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
objectiveThe Women's Health Initiative randomized hormone trials unexpectedly demonstrated an increase in early coronary events. In an effort to explain this finding, we examined lipoprotein particle concentrations and their interactions with hormone therapy in a case-control substudy. METHODS AND
resultsWe randomized 16 608 postmenopausal women with intact uterus to conjugated estrogens 0.625 mg with medroxyprogesterone acetate 2.5 mg daily or to placebo, and 10 739 women with prior hysterectomy to conjugated estrogens 0.625 mg daily or placebo, and measured lipoprotein subclasses by nuclear magnetic resonance spectroscopy at baseline and year 1 in 354 women with early coronary events and matched controls. Postmenopausal hormone therapy raised high-density lipoprotein cholesterol and particle concentration and reduced low-density lipoprotein cholesterol (LDL-C; all P<0.001 versus placebo). In contrast, neither unopposed estrogen nor estrogen with progestin lowered low-density lipoprotein particle concentration (LDL-P).
conclusionsPostmenopausal hormone therapy-induced reductions in LDL-C were not paralleled by favorable effects on LDL-P. This finding may account for the absence of coronary protection conferred by estrogen in the randomized hormone trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.